Tucso , AZ, Septembe 14, 2026 –(PR.com)– Mic ovascula The apeutics, I c. (MVT), a cli ical-stage biotech ology compa y developi g ult asou d-based diag ostic a d the apeutic tech ologies, today a ou ced publicatio of a U ive sity of Utah study evaluati g MVT-101 phase-shift a obubbles with focused ult asou d fo o -the mal b ai tissue ablatio . The study, “Histology-Validated Qua titative MRI Assessme t of No -The mal Focused Ult asou d Ablatio ,” was published i Scie tific Repo ts o July 24, 2026. Resea che s f om the U ive sity of Utah used MVT-101 with t a sc a ial focused ult asou d to c eate highly localized mecha ical tissue effects without elyi g o heat. The wo k also evaluated MRI methods fo ide tifyi g whe e t eatme t occu ed.
Pote tial Adva tages of the MVT Na obubble App oachThe tech ology could offe seve al pote tial adva tages ove co ve tio al the mal focused ult asou d:· Lowe ult asou d e e gy a d less heati g: which may educe limitatio s associated with heati g of the skull.· Small a obubble size: which may imp ove access to tumo blood vessels a d su ou di g tumo tissue.· P ecise, image-guided t eatme t: pote tially allowi g physicia s to ta get difficult-to- each tumo s while limiti g effects o su ou di g healthy tissue.
“Phase-shift a obubbles could allow focused ult asou d to dest oy ta geted tissue usi g less e e gy a d less heati g tha co ve tio al the mal ablatio ,” said He ik Odée , Ph.D., se io autho of the study at the U ive sity of Utah. “This study also shows that MRI ca help us dete mi e whe e t eatme t occu ed, a impo ta t step towa d t a slati g this app oach to patie ts.”
MRI Co fi ms T eatme t Locatio I ats, MRI accu ately ide tified the a ea of b ai tissue t eated with MVT-101 a d focused ult asou d. Combi i g seve al MRI sca s with machi e-lea i g a alysis imp oved detectio by app oximately 45% compa ed with a si gle MRI sca . The app oach also pe fo med well i tumo -bea i g a imals, suppo ti g its pote tial use i MRI-guided focused-ult asou d t eatme t of b ai tumo s. “This app oach could p ovide a ew way to dest oy tumo s without su ge y o the heat equi ed fo co ve tio al focused ult asou d,” said Emma uelle J. Meuillet, Ph.D., Chief Ope ati g a d Scie tific Office of Mic ovascula The apeutics. “Equally impo ta t, MRI may allow physicia s to see whe e t eatme t occu ed, helpi g make the the apy mo e p ecise.”
A Pote tial New App oach to Difficult-to-T eat B ai Tumo sCo ve tio al focused ult asou d dest oys tissue with heat, which ca limit t eatme t th ough the skull a d est ict the size a d locatio of tumo s that ca be t eated.MVT’s Na oBlate™ platfo m i stead uses i t ave ously admi iste ed phase-shift a obubbles that a e activated o ly whe e focused ult asou d is applied. The esulti g mecha ical effects may p ovide a o -i vasive way to ta get tumo tissue while educi g heati g of su ou di g st uctu es.
“This ep ese ts a impo ta t step towa d ou visio fo Na oBlate,” said Meuillet. “Ou goal is a i t ave ously admi iste ed a obubble that eaches a tumo a d is activated o ly whe e focused ult asou d is applied.”
About the StudyResea che s tested MVT-101 with focused ult asou d i a imal models a d used MRI to assess the t eated a eas. The study showed that MRI could help ide tify a d mo ito t eatme t effects, suppo ti g the pote tial developme t of MRI-guided focused-ult asou d the apy fo b ai tumo s. The esea ch was suppo ted by Hu tsma Ca ce I stitute, the Ame ica Ca ce Society, the U ive sity of Utah, a d the Natio al I stitutes of Health.
About Mic ovascula The apeuticsMic ovascula The apeutics, I c. is developi g a platfo m of ext-ge e atio ult asou d co t ast a d the apeutic age ts based o p op ieta y mic obubble a d a obubble tech ologies.
· Ca diSo ™, a ext-ge e atio ult asou d e ha ci g age t;· Solv™, a ult asou d-activated phase-shift a obubble the apy bei g developed fo mic ovascula obst uctio followi g myoca dial i fa ctio ; a d· Na oBlate™, a a obubble-e abled focused-ult asou d platfo m fo o -i vasive tumo ablatio .
I vestigatio al P oduct Disclaime MVT-101 a d Na oBlate™ a e i vestigatio al p oducts a d have ot bee app oved o clea ed by the U.S. Food a d D ug Admi ist atio o a y othe egulato y autho ity. Thei safety a d effective ess i huma s have ot bee established. Results desc ibed i this elease a e f om p ecli ical studies a d may ot be p edictive of esults i huma cli ical t ials.
Fo wa d-Looki g Stateme tsThis p ess elease co tai s fo wa d-looki g stateme ts ega di g the developme t a d pote tial applicatio s of MVT’s phase-shift a obubble tech ology, MVT-101 a d Na oBlate™, i cludi g thei pote tial use fo focused-ult asou d tumo ablatio a d pote tial adva tages elative to existi g the apeutic app oaches. These stateme ts a e based o cu e t expectatio s a d p ecli ical fi di gs a d a e subject to isks a d u ce tai ties. The e ca be o assu a ce that these tech ologies will demo st ate safety o efficacy i huma s, successfully complete cli ical developme t, o eceive egulato y app oval.
